Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zolpidem Clear all
Completed Phase 4 Interventional Results available

Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia

NCT03774810
View directory record Official record
Conditions
Insomnia, Insomnia Chronic
Interventions
Zolpidem tartrate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Improving Sleep Quality in Heart Failure

NCT03307005
View directory record Official record
Conditions
Sleep Disturbance, Heart Failure
Interventions
Zolpidem Tartrate, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 79 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia

NCT00492232
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon and zolpidem, Placebo and zolpidem
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Hot Springs, Arkansas • Anaheim, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

NCT00156533
View directory record Official record
Conditions
Insomnia, Primary Insomnia, Psychophysiologic Insomnia
Interventions
Zolpidem, Sugar Pill
Drug
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety and Efficacy of Chronic Hypnotic Use

NCT01006525
View directory record Official record
Conditions
Primary Insomnia
Interventions
zolpidem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

NCT02783729
View directory record Official record
Conditions
Insomnia
Interventions
Lemborexant, Lemborexant-matched placebo, Zolpidem tartrate, Zolpidem-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
60
States / cities
Jasper, Alabama • Glendale, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

NCT00084669
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Sleep Disorders
Interventions
venlafaxine, zolpidem tartrate, management of therapy complications
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

NCT03056053
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Santa Monica, California • Atlanta, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.

NCT00383643
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
zolpidem tartrate, sodium oxybate, Matching Placebos
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)

NCT00425243
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
zolpidem-MR (SL800750)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2009 · Synced Sep 1, 2026, 10:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 1, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

NCT00683436
View directory record Official record
Conditions
Primary Insomnia
Interventions
Adipiplon, Placebo, Ambien CR
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
21 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Pembroke Pines, Florida • South Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions

NCT00833521
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 1, 2026, 10:24 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

NCT00781482
View directory record Official record
Conditions
Healthy
Interventions
eszopiclone, zolpidem, placebo
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years to 35 Years · Male only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Combined Behavioral/Pharmacological Therapy for Insomnia

NCT00044629
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
Cognitive-Behavioral Therapy for Insomnia, zolpidem tartrate (Ambien), Placebo
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2013 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

CBT-I or Zolpidem/Trazodone for Insomnia

NCT04468776
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Zolpidem, Internet Cognitive Behavioral Therapy for Insomnia (CBT-I), Trazodone
Drug · Behavioral
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Columbia, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Two Contrasting Interventions for Sleep Management

NCT01804036
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
Zolpidem, Mind-Body Bridging
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
17 Years to 40 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

NCT00676026
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine, Zolpidem, Progesterone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 1, 2026, 10:24 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 1, 2026, 10:24 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T

NCT01747590
View directory record Official record
Conditions
Psychotropic Drugs Effects
Interventions
Zolpidem, Alprazolam, Caffeine, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

NCT02353299
View directory record Official record
Conditions
Healthy
Interventions
Silenor 6 mg, zolpidem 10 mg, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Novi, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep

NCT01485393
View directory record Official record
Conditions
Insomnia
Interventions
Dexmedetomidine, Zolpidem
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

NCT00716521
View directory record Official record
Conditions
Methodology Study
Interventions
placebo, zolpidem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Sep 1, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions

NCT00833937
View directory record Official record
Conditions
Healthy
Interventions
Zolpidem 10 mg tablets, AMBIEN® 10 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 1, 2026, 10:24 PM EDT